Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study

Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter Proteins

(2010) Xiao-Kun Wang et al.   CURRENT DRUG METABOLISM

Distribution, metabolism, and excretion of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs

(2010) M. F. YANCEY et al.   JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs*

(2010) K. M. Rassnick et al.   Veterinary and Comparative Oncology

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2

(2009) Chun-ling Dai et al.   CANCER LETTERS

Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision

(2009) C. A. London et al.   CLINICAL CANCER RESEARCH

Phase I Dose Escalation of Single-Agent Vinblastine in Dogs

(2009) D.B. Bailey et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Efficacy of Vinblastine for Treatment of Canine Mast Cell Tumors

(2009) K.M. Rassnick et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

(2008) S. Shukla et al.   DRUG METABOLISM AND DISPOSITION

Dose-escalating vinblastine for the treatment of canine mast cell tumour

(2008) K. R. Vickery et al.   Veterinary and Comparative Oncology